Across TCGA pan-cancer cohorts, FAM111B RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated FAM111B data layer compared with 5 for mutation status and 5 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher FAM111B RNA is associated with worse overall survival. In most high-consensus cancer types, elevated FAM111B expression acts as an unfavorable survival marker, although some lineages such as READ and OV show a favorable association.
ACC, KIRP, and MESO are the cancer types where FAM111B RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.